Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database.

Ataxia Autoantibodies Cell Adhesion Molecules Contactin 1 Humans Nerve Growth Factors Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / epidemiology

Anti-nerve antibodies CIDP Chronic inflammatory demyelinating polyradiculoneuropathy Peripheral neuropathy anti-ganglioside antibodies paranodopathy

Journal

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

ISSN: 1590-3478

Titre abrégé: Neurol Sci

Pays: Italy

ID NLM: 100959175

Informations de publication

Date de publication:
Jun 2022

Historique:

received: 15 08 2021

accepted: 04 12 2021

pubmed: 21 1 2022

medline: 24 5 2022

entrez: 20 1 2022

Statut: ppublish

Résumé

To investigate the frequency and clinical correlates of anti-nerve autoantibodies in an unselected series of Italian patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) METHODS: Sera from 276 CIDP patients fulfilling the EFNS/PNS criteria and included in the Italian CIDP database were examined for the presence of anti-nerve autoantibodies. Results were correlated with the clinical data collected in the database. Anti-neurofascin155 (NF155) antibodies were found in 9/258 (3.5%) patients, anti-contactin1 (CNTN1) antibodies in 4/258 (1.6%) patients, and anti-contactin-associated protein1 (Caspr1) in 1/197 (0.5%) patients, while none had reactivity to gliomedin or neurofascin 186. Predominance of IgG4 isotype was present in 7of the 9 examined patients. Anti-NF155 patients more frequently had ataxia, tremor, and higher CSF protein levels than antibody-negative patients. Anti-CNTN1 patients more frequently had a GBS-like onset, pain, and ataxia and had more severe motor impairment at enrollment than antibody-negative patients. They more frequently received plasmapheresis, possibly reflecting a less satisfactory response to IVIg or steroids. IgM antibodies against one or more gangliosides were found in 6.5% of the patients (17/260) and were more frequently directed against GM1 (3.9%). They were frequently associated with a progressive course, with a multifocal sensorimotor phenotype and less frequent cranial nerve involvement and ataxia. Anti-paranodal and anti-ganglioside antibodies are infrequent in patients with CIDP but are associated with some typical clinical association supporting the hypothesis that CIDP might be a pathogenically heterogeneous syndrome possibly explaining the different clinical presentations.

Identifiants

DOI: 10.1007/s10072-021-05811-0 PMID: 35048233

pubmed: 35048233

doi: 10.1007/s10072-021-05811-0

pii: 10.1007/s10072-021-05811-0

doi:

Substances chimiques

Autoantibodies 0

Cell Adhesion Molecules 0

Contactin 1 0

Nerve Growth Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

3939-3947

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Références

Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC (2019) Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 52(3-4):161–172. https://doi.org/10.1159/000494291

doi: 10.1159/000494291 pubmed: 30669140

Mathey EK, Park SB, Hughes RAC et al (2015) Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 86(9):973–985. https://doi.org/10.1136/jnnp-2014-309697

doi: 10.1136/jnnp-2014-309697 pubmed: 25677463

Doneddu PE, Nobile-Orazio E (2018) Management of chronic inflammatory demyelinating polyradiculopathy. Curr Opin Neurol 31(5):511–516. https://doi.org/10.1097/WCO.0000000000000595

doi: 10.1097/WCO.0000000000000595 pubmed: 30045075

Doneddu PE, Cocito D, Manganelli F et al (2019) Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry 90(2):125–132. https://doi.org/10.1136/jnnp-2018-318714

doi: 10.1136/jnnp-2018-318714 pubmed: 30297520

Kieseier BC, Mathey EK, Sommer C, Hartung H-P (2018) Immune-mediated neuropathies. Nat Rev Dis Primer 4(1):31. https://doi.org/10.1038/s41572-018-0027-2

doi: 10.1038/s41572-018-0027-2

Ng JKM, Malotka J, Kawakami N et al (2012) Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 79(23):2241–2248. https://doi.org/10.1212/WNL.0b013e31827689ad

doi: 10.1212/WNL.0b013e31827689ad pubmed: 23100406 pmcid: 3542349

Querol L, Nogales-Gadea G, Rojas-Garcia R et al (2014) Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 82(10):879–886. https://doi.org/10.1212/WNL.0000000000000205

doi: 10.1212/WNL.0000000000000205 pubmed: 24523485 pmcid: 3959751

Ogata H, Yamasaki R, Hiwatashi A et al (2015) Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2(10):960–971. https://doi.org/10.1002/acn3.248

doi: 10.1002/acn3.248 pubmed: 26478896 pmcid: 4603379

Devaux JJ, Miura Y, Fukami Y et al (2016) Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 86(9):800–807. https://doi.org/10.1212/WNL.0000000000002418

doi: 10.1212/WNL.0000000000002418 pubmed: 26843559 pmcid: 4793783

Cortese A, Lombardi R, Briani C et al (2020) Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Neurol - Neuroimmunol Neuroinflamm 7(1):e639. https://doi.org/10.1212/NXI.0000000000000639

doi: 10.1212/NXI.0000000000000639 pubmed: 31753915

Kadoya M, Kaida K, Koike H et al (2016) IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. J Neuroimmunol 301:16–22. https://doi.org/10.1016/j.jneuroim.2016.10.013

doi: 10.1016/j.jneuroim.2016.10.013 pubmed: 27852440

Mathey EK, Garg N, Park SB et al (2017) Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. J Neuroimmunol 309:41–46. https://doi.org/10.1016/j.jneuroim.2017.05.002

doi: 10.1016/j.jneuroim.2017.05.002 pubmed: 28601286

Delmont E, Manso C, Querol L et al (2017) Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain. 140(7):1851–1858. https://doi.org/10.1093/brain/awx124

doi: 10.1093/brain/awx124 pubmed: 28575198

Burnor E, Yang L, Zhou H et al (2018) Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies. Neurology. 90(1):e31–e38. https://doi.org/10.1212/WNL.0000000000004773

doi: 10.1212/WNL.0000000000004773 pubmed: 29187518 pmcid: 5754648

Querol L, Nogales-Gadea G, Rojas-Garcia R et al (2013) Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy: contactin-1 in Aggressive CIDP. Ann Neurol 73(3):370–380. https://doi.org/10.1002/ana.23794

doi: 10.1002/ana.23794 pubmed: 23280477

Miura Y, Devaux JJ, Fukami Y et al (2015) Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain. 138(6):1484–1491. https://doi.org/10.1093/brain/awv054

doi: 10.1093/brain/awv054 pubmed: 25808373 pmcid: 4614146

Doppler K, Appeltshauser L, Wilhelmi K et al (2015) Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry 86(7):720–728. https://doi.org/10.1136/jnnp-2014-309916

doi: 10.1136/jnnp-2014-309916 pubmed: 25694474

Doppler K, Appeltshauser L, Villmann C et al (2016) Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain. 139(10):2617–2630. https://doi.org/10.1093/brain/aww189

doi: 10.1093/brain/aww189 pubmed: 27474220

Klehmet J, Märschenz S, Ruprecht K et al (2018) Analysis of anti-ganglioside antibodies by a line immunoassay in patients with chronic-inflammatory demyelinating polyneuropathies (CIDP). Clin Chem Lab Med CCLM 56(6):919–926. https://doi.org/10.1515/cclm-2017-0792

doi: 10.1515/cclm-2017-0792 pubmed: 29329103

Martinez-Thompson JM, Snyder MR, Ettore M et al (2018) Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM. Muscle Nerve 57(6):1000–1005. https://doi.org/10.1002/mus.26051

doi: 10.1002/mus.26051 pubmed: 29272035

Querol L, Siles AM, Alba-Rovira R et al (2017) Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep 7(1):14411. https://doi.org/10.1038/s41598-017-14853-4

doi: 10.1038/s41598-017-14853-4 pubmed: 29089585 pmcid: 5663697

Liberatore G, Manganelli F, Doneddu PE et al (2020) Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria? Eur J Neurol. Published online October 15, ene.14545. https://doi.org/10.1111/ene.14545

Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision. J Peripher Nerv Syst 15(1):1–9. https://doi.org/10.1111/j.1529-8027.2010.00245.x

doi: 10.1111/j.1529-8027.2010.00245.x

Liberatore G, Giannotta C, Sajeev BP et al (2020) Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy. J Neuroimmunol 345:577288. https://doi.org/10.1016/j.jneuroim.2020.577288

doi: 10.1016/j.jneuroim.2020.577288 pubmed: 32544754

Nobile-Orazio E, Terenghi F, Giannotta C, Gallia F, Nozza A (2009) Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. Neurology. 72(11):1024–1026. https://doi.org/10.1212/01.wnl.0000344569.13496.ff

doi: 10.1212/01.wnl.0000344569.13496.ff pubmed: 19289745

Nobile-Orazio E, Gallia F, Terenghi F, Allaria S, Giannotta C, Carpo M (2008) How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci 266(1-2):156–163. https://doi.org/10.1016/j.jns.2007.09.020

doi: 10.1016/j.jns.2007.09.020 pubmed: 17915254

Hughes RAC, Bensa S, Willison HJ et al (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195–201. https://doi.org/10.1002/ana.1088

doi: 10.1002/ana.1088 pubmed: 11506402

Breiner A, Bourque PR, Allen JA (2019) Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis. Muscle Nerve 60(2):180–183. https://doi.org/10.1002/mus.26488

doi: 10.1002/mus.26488 pubmed: 30989684

Zhang X, Zheng P, Devaux JJ et al (2019) Chronic inflammatory demyelinating polyneuropathy with anti-NF155 IgG4 in China. J Neuroimmunol 337:577074. https://doi.org/10.1016/j.jneuroim.2019.577074

doi: 10.1016/j.jneuroim.2019.577074 pubmed: 31693967

Delmont E, Brodovitch A, Kouton L et al (2020) Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. J Neurol 267(12):3664–3672. https://doi.org/10.1007/s00415-020-10041-z

doi: 10.1007/s00415-020-10041-z pubmed: 32676765

Cortese A, Devaux JJ, Zardini E et al (2016) Neurofascin-155 as a putative antigen in combined central and peripheral demyelination. Neurol Neuroimmunol Neuroinflamma 3(4):e238. https://doi.org/10.1212/NXI.0000000000000238

doi: 10.1212/NXI.0000000000000238

Kuwahara M, Suzuki H, Samukawa M, Hamada Y, Takada K, Kusunoki S (2013) Clinical features of CIDP with LM1-associated antibodies. J Neurol Neurosurg Psychiatry 84(5):573–575. https://doi.org/10.1136/jnnp-2012-303440

doi: 10.1136/jnnp-2012-303440 pubmed: 23138763

Nobile-Orazio E (2014) Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst 19(1):2–13. https://doi.org/10.1111/jns5.12053

doi: 10.1111/jns5.12053 pubmed: 24612201